Protocol Ledger

NCT03504423 · Phase III · COMPLETED

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Interventional Phase III clinical trial protocol NCT03504423 sponsored by Cornerstone Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-11-09 Enrollment: 528 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03504423
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)528 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03504423
Protocol FieldVerified Registry Value
NCT IdentifierNCT03504423
Consolidated Lead SponsorCornerstone Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment528 participants (ACTUAL)
Registered Start Date2018-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI